SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.+67.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SAVA vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.61B
5Y Perf.-35.9%
SAVA vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SAVA | PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $94M | $7.61B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-106M | $-303M |
| Total Debt | $0.00 | $110K |
| Cash & Equiv. | $129M | $357M |
SAVA vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SAVA
PRAX
| Stock | Oct 20 | Mar 26 | Return |
|---|---|---|---|
| Cassava Sciences, I… (SAVA) | 100 | 167.1 | +67.1% |
| Praxis Precision Me… (PRAX) | 100 | 64.1 | -35.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SAVA vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRAX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Cassava Sciences, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 77.6%
- -18.5% 10Y total return vs PRAX's -19.0%
- 5.4% margin vs PRAX's 2.4%
Best for: growth exposure and long-term compounding
PRAX
Praxis Precision Medicines, Inc.
The Income Pick
PRAX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.55
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
- Beta 1.55, current ratio 10.22x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRAX | -100.0% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs PRAX's 2.4% |
| Stability / Safety | PRAX | Beta 1.55 vs SAVA's 2.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PRAX | +8.6% vs SAVA's +29.5% |
| Efficiency (ROA) | PRAX | -53.5% ROA vs SAVA's -75.3%, ROIC -65.0% vs -6.3% |
SAVA vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
SAVA vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGSAVA
SAVACassava Sciences, Inc.
1leads
PRAXPraxis Precision Medi…
3leads
6 Total Categories
CATEGORYLEADERvs SAVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX5/6
Risk & VolatilityBeta, volatility, and downside exposure
PRAX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SAVA and PRAX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SAVACassava Sciences,… | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$110M | -$326M |
| Net IncomeAfter-tax profit | -$106M | -$303M |
| Free Cash FlowCash after capex | -$84M | -$249M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +62.1% | -19.0% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SAVA and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SAVACassava Sciences,… | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $94M | $7.6B |
| Enterprise ValueMkt cap + debt − cash | -$34M | $7.2B |
| Trailing P/EPrice ÷ TTM EPS | -3.76x | -25.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.63x | 8.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SAVA and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
PRAX delivers a -58.7% return on equity — every $100 of shareholder capital generates $-59 in annual profit, vs $-96 for SAVA. On the Piotroski fundamental quality scale (0–9), PRAX scores 3/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | SAVACassava Sciences,… | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -95.8% | -58.7% |
| ROA (TTM)Return on assets | -75.3% | -53.5% |
| ROICReturn on invested capital | -6.3% | -65.0% |
| ROCEReturn on capital employed | -99.9% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$129M | -$357M |
| Cash & Equiv.Liquid assets | $129M | $357M |
| Total DebtShort + long-term debt | $0 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
PRAX leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $8,157 today (with dividends reinvested), compared to $3,275 for SAVA. Over the past 12 months, PRAX leads with a +860.9% total return vs SAVA's +29.5%. The 3-year compound annual growth rate (CAGR) favors PRAX at 176.1% vs SAVA's -16.0% — a key indicator of consistent wealth creation.
| Metric | SAVACassava Sciences,… | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | +18.0% |
| 1-Year ReturnPast 12 months | +29.5% | +860.9% |
| 3-Year ReturnCumulative with dividends | -40.8% | +2005.6% |
| 5-Year ReturnCumulative with dividends | -67.3% | -18.4% |
| 10-Year ReturnCumulative with dividends | -18.5% | -19.0% |
| CAGR (3Y)Annualised 3-year return | -16.0% | +176.1% |
PRAX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PRAX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRAX is the less volatile stock with a 1.55 beta — it tends to amplify market swings less than SAVA's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 94.9% from its 52-week high vs SAVA's 39.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SAVACassava Sciences,… | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 1.55x |
| 52-Week HighHighest price in past year | $4.98 | $356.00 |
| 52-Week LowLowest price in past year | $1.45 | $34.89 |
| % of 52W HighCurrent price vs 52-week peak | +39.3% | +94.9% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 53.7 |
| Avg Volume (50D)Average daily shares traded | 720K | 376K |
PRAX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SAVA as "Buy" and PRAX as "Buy".
| Metric | SAVACassava Sciences,… | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $544.40 |
| # AnalystsCovering analysts | 12 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SAVA leads in 1 (Income & Cash Flow). 1 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 3 of 6 categories
Loading custom metrics...
SAVA vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SAVA or PRAX a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SAVA or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -18. 4%, compared to -67. 3% for Cassava Sciences, Inc. (SAVA). Over 10 years, the gap is even starker: SAVA returned -18. 5% versus PRAX's -19. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SAVA or PRAX?
By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.
(PRAX) is the lower-risk stock at 1. 55β versus Cassava Sciences, Inc. 's 2. 02β — meaning SAVA is approximately 31% more volatile than PRAX relative to the S&P 500.
04Which is growing faster — SAVA or PRAX?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SAVA or PRAX?
Cassava Sciences, Inc.
(SAVA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SAVA leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — SAVA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SAVA or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SAVA or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Praxis Precision Medicines, Inc.
(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cassava Sciences, Inc. (SAVA) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRAX: -19. 0%, SAVA: -18. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SAVA and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.